PARP inhibitor rucaparib becomes new treatment option for some men with advanced prostate cancer
Results from an international clinical trial found that men with advanced prostate cancer who have…
Browsing: rucaparib
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration (FDA) granted accelerated approval to rucaparib for patients with deleterious…
AACR 2019: PARP inhibitors can shrink tumours in pancreatic cancer patients with specific mutations
Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead of continuing…
AACR 2019: Maintenance therapy with rucaparib shows clinical responses in a subgroup of patients with pancreatic cancer
Maintenance treatment with the PARP inhibitor rucaparib was well tolerated and provided clinical responses among…
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including…
New trial updates for rucaparib for advanced ovarian cancer
New data from parts 1 and 2 of the ongoing ARIEL2 phase II trial was presented…